Q3 EPS Estimate for ArriVent BioPharma Raised by Analyst

Key Points

• HC Wainwright raised their Q3 2025 EPS estimate for ArriVent BioPharma to ($0.82), up from ($0.83), while maintaining a "Buy" rating and a price target of $42.00.
• ArriVent BioPharma reported Q2 earnings of ($0.90) per share, missing the consensus estimate by ($0.20).
• The stock has received mixed ratings, with one sell, six buy, and one strong buy, leading to an average rating of "Moderate Buy" and a consensus target price of $39.14.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for ArriVent BioPharma in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.82) per share for the quarter, up from their prior estimate of ($0.83). HC Wainwright currently has a "Buy" rating and a $42.00 target price on the stock. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma's Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($4.30) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.47) EPS.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.20).

A number of other analysts have also weighed in on AVBP. Zacks Research upgraded ArriVent BioPharma from a "strong sell" rating to a "hold" rating in a report on Monday. Wall Street Zen lowered ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Oppenheimer restated an "outperform" rating and set a $44.00 target price (up previously from $39.00) on shares of ArriVent BioPharma in a report on Tuesday, June 24th. Jones Trading began coverage on ArriVent BioPharma in a report on Tuesday, May 20th. They set a "buy" rating and a $40.00 target price for the company. Finally, Guggenheim reiterated a "buy" rating and set a $45.00 price objective on shares of ArriVent BioPharma in a report on Tuesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $39.14.

ArriVent BioPharma Stock Performance

ArriVent BioPharma stock traded up $0.07 during mid-day trading on Friday, reaching $19.27. 224,215 shares of the company were exchanged, compared to its average volume of 258,799. The business has a fifty day moving average of $21.21 and a 200 day moving average of $21.35. The firm has a market cap of $781.76 million, a P/E ratio of -4.79 and a beta of 1.17. ArriVent BioPharma has a 12-month low of $15.47 and a 12-month high of $36.37.

Hedge Funds Weigh In On ArriVent BioPharma

Several hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC increased its position in shares of ArriVent BioPharma by 21.7% in the 4th quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company's stock valued at $59,833,000 after acquiring an additional 400,838 shares during the period. Infinitum Asset Management LLC increased its position in shares of ArriVent BioPharma by 25.7% in the 1st quarter. Infinitum Asset Management LLC now owns 2,066,238 shares of the company's stock valued at $38,205,000 after acquiring an additional 422,315 shares during the period. Octagon Capital Advisors LP increased its position in shares of ArriVent BioPharma by 4.2% in the 4th quarter. Octagon Capital Advisors LP now owns 2,059,387 shares of the company's stock valued at $54,862,000 after acquiring an additional 83,000 shares during the period. Novo Holdings A S increased its position in shares of ArriVent BioPharma by 1.0% in the 4th quarter. Novo Holdings A S now owns 1,520,627 shares of the company's stock valued at $40,510,000 after acquiring an additional 15,312 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of ArriVent BioPharma by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 1,503,358 shares of the company's stock valued at $27,797,000 after acquiring an additional 86,067 shares during the period. 9.48% of the stock is owned by institutional investors and hedge funds.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.